1339. Results for the supplemental microbiological modified intent-to-treat (SmMITT) population of the RESTORE-IMI 1 trial of imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients (pts) with imipenem-nonsusceptible (NS) bacterial infections
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • 18-1315-D MRPAB18303 IDWeek SmMITT_final.pdf (411.6 kB)
  • Background: Clinical trials of new antibacterial agents in pts with carbapenem-resistant infections are critical but challenging to conduct. One challenge is identifying the study population by microbiological (micro) criteria; pts need to be identified locally to initiate effective treatment rapidly, but data standardization requires central laboratory confirmation. REL is a novel β-lactamase inhibitor that can restore imipenem activity against many imipenem-NS gram-negative pathogens. Here we compare a supplemental analysis population based on local microbiology data (SmMITT eligibility) with the primary analysis population (mMITT) from the RESTORE-IMI 1 trial (NCT02452047) of IMI/REL vs IMI+CST.

     

    Methods: Randomized, active-controlled, double-blind, phase 3 trial enrolled adults with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), complicated intra-abdominal infection (cIAI), or complicated urinary tract infection (cUTI). Pts were mMITT-eligible if pathogens were imipenem-NS (but CST- and IMI/REL-susceptible) based on central lab minimum inhibitory concentration (MIC). SmMITT comprised mMITT plus all pts who met inclusion criteria only based on local lab MIC.

     

    Results: The SmMITT population (n=41 [28 IMI/REL; 13 IMI+CST]) comprised 31 from mMITT plus 10 based on local MIC; 12/41 (29%) had HABP/VABP, 8/41 (20%) cIAI, and 21/41 (51%) cUTI. The majority of differences in central vs local MIC were 1-2 dilutions; similar numbers of pts were excluded from mMITT due to imipenem susceptibility (n=5) or IMI/REL-NS (n=4); 1 patient was CST-NS. Baseline characteristics, including infecting pathogens, were comparable in SmMITT and mMITT (SmMITT: 68% male; 46% ≥65 y; 24% APACHE II score >15; 22% creatinine clearance <60 mL/min). Rates of efficacy outcomes (overall response, day 28 clinical response, day 28 mortality) were comparable between populations, except that response rates in pts with cIAI were higher in SmMITT (Table).

     

    Conclusion: Consistency of results was demonstrated across 2 analysis populations in a trial of resistant pathogens. This analysis provides results supportive of expected future clinical use of IMI/REL when treatment decisions will be made based on local lab results.

     

    Keith Kaye, MD, MPH1, Thomas File, MD2, Helen W. Boucher, MD, FIDSA3, Michelle Brown, RN4, Angela Aggrey, PhD4, Ireen Khan, MD4, Hee-Koung Joeng, PhD4, Robert Tipping, MS4, Jiejun Du, PhD4, Katherine Young, MS4, Joan Butterton, MD4, Nicholas A. Kartsonis, MD4 and Amanda Paschke, MD, MSCE4, (1)University of Michigan, Ann Arbor, MI, (2)Summa Health System, Akron, OH, (3)Infectious Diseases, Tufts Medical Center, Boston, MA, (4)Merck & Co., Inc., Kenilworth, NJ

    Disclosures:

    K. Kaye, Merck & Co., Inc.: Consultant and Research Contractor , Research grant . Melinta, Achaogen, Allergan: Consultant , Consulting fee .

    T. File, Bio Merieux, Curetis, Melinta, Merck, MotifBio, Nabriva, Paratek, Pfizer: Consultant , Consulting fee .

    H. W. Boucher, Merck & Co., Inc.: Scientific Advisor , Consulting fee .

    M. Brown, Merck & Co., Inc.: Employee , Salary .

    A. Aggrey, Merck & Co., Inc.: Employee , Salary .

    I. Khan, Merck & Co., Inc.: Employee , Salary .

    H. K. Joeng, Merck & Co., Inc.: Employee , Salary .

    R. Tipping, Merck & Co., Inc.: Employee , Salary .

    J. Du, Merck & Co., Inc.: Employee , Salary .

    K. Young, Merck & Co., Inc.: Employee , Salary and Stock options .

    J. Butterton, Merck & Co., Inc.: Employee , Salary and Stock .

    N. A. Kartsonis, Merck & Co., Inc.: Employee , Salary and Stocks .

    A. Paschke, Merck & Co., Inc.: Employee and Shareholder , Salary .

    See more of: Novel Agents
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.